Combination therapy for colorectal cancer with liver tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests a combination of three drugs for patients with colorectal cancer that has spread to the liver. The goal is to see if this combination can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have colorectal cancer that has spread to your liver, and you have at least one measurable tumor in the liver.
- Your cancer is a type called MSS (microsatellite stable), which means it does not have a certain genetic marker that makes it respond to some immunotherapies.
- You have already received at least one round of chemotherapy that included fluorouracil, oxaliplatin, and irinotecan, and possibly other targeted drugs like bevacizumab or an EGFR inhibitor.
- You are generally able to take care of yourself (ECOG performance status 0 or 1) and have a life expectancy of at least 12 weeks.
- Your blood counts, kidney, and liver functions are within acceptable ranges.
- You have not received immunotherapy (like PD-1 or PD-L1 inhibitors) before.
- You do not have major heart disease, uncontrolled infections, active autoimmune disease, or other serious conditions that would make the trial unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combinations of immunotherapy drugs for people with colorectal cancer that has spread to the liver and is scheduled for surgery. The goal is to see if these treatments are safe and effective before and after the operation.
This trial tests a mix of three drugs (sintilimab, bevacizumab, and decitabine) for people with advanced colorectal cancer that has a stable or low amount of genetic change. It’s for those whose cancer has grown after at least two prior treatments, and who have not had immunotherapy before.
This trial tests a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus chemotherapy for people with a specific type of colorectal cancer that hasn't spread to the liver. It may be an option if your cancer is mismatch repair stable (MSS or pMMR) and has progressed after initial treatment.
This trial tests a new drug called BioTTT001 combined with toripalimab and regorafenib for people with colorectal cancer that has spread to the liver. It is for those who have tried at least two prior treatments or cannot have standard therapies.
This trial tests the combination of two immunotherapy drugs (botensilimab and balstilimab) plus targeted radiation to liver tumors. It's for people with colorectal cancer that has spread and hasn't responded to standard treatments.
This trial tests two new immunotherapy drugs (botensilimab and balstilimab) given after standard treatment for stage II or III colorectal cancer. The drugs are designed to boost your immune system to prevent cancer from coming back, especially if cancer cells are detected in your blood.
Hear when a new Colorectal Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.